Dolat Capital: Dabur India Q2 Review - Healthcare Continues To Post Strong Growth
A range of Dabur India Ltd. products is displayed at the company’s head office in Ghaziabad, India (Photographer Prashanth Vishwanathan/Bloomberg)

Dolat Capital: Dabur India Q2 Review - Healthcare Continues To Post Strong Growth

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Dolat Capital Report

Dabur India Ltd.’s Q2 FY21 results exceed our estimate. Domestic fast moving consumer goods volumes increased by 16.8% YoY.

Growth in the domestic market was driven by health care (up 49.3%) and home and personal care (9.1%) business.

Healthcare contribution grew from 32% in Q2 FY20 to 40% in Q2 FY21 led by two times growth in Chyawanprash and double digit growth in honey indicates change in consumer preferences.

We believe that the healthcare category would continue to grow faster post Covid-19 with new launches.

Click on the attachment to read the full report:

Dolat Capital Dabur India Q2FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.